ALLMedicine™ Systemic Mastocytosis Center
Research & Reviews 411 results
https://clinicaltrials.gov/ct2/show/NCT03770273
May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://clinicaltrials.gov/ct2/show/NCT00001756
May 20th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...
https://doi.org/10.1016/j.jaci.2022.04.025
The Journal of Allergy and Clinical Immunology; Giannetti MP, Godwin G et. al.
May 14th, 2022 - Patients with systemic mastocytosis often have symptoms of mast cell activation which is associated with elevated levels of urinary mast cell mediator metabolites. Patients with hereditary alpha-tryptasemia (HαT) may present with symptoms of mast ...
https://doi.org/10.1016/j.jaci.2022.04.023
The Journal of Allergy and Clinical Immunology; Boehm T, Ristl R et. al.
May 4th, 2022 - In subjects with systemic mastocytosis the number of mast cells is elevated manifold. These patients frequently suffer unpredictable and recurrent life-threatening mast cell activation (MCA) events. Our aim was to analyze the derangements of chemo...
https://doi.org/10.1182/bloodadvances.2022006969
Blood Advances; Wu C, Boey D et. al.
May 3rd, 2022 - Mast cell accumulation is a hallmark of a number of diseases including allergic asthma and systemic mastocytosis. IgE-mediated crosslinking of the FceRI receptors causes mast cell activation and contributes to disease pathogenesis. The mast cell l...
Guidelines 1 results
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Drugs 191 results see all →
Clinicaltrials.gov 16 results
https://clinicaltrials.gov/ct2/show/NCT03770273
May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://clinicaltrials.gov/ct2/show/NCT00001756
May 20th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...
https://clinicaltrials.gov/ct2/show/NCT03214666
Apr 1st, 2022 - This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanc...
https://clinicaltrials.gov/ct2/show/NCT03580655
Mar 28th, 2022 - This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neopl...
https://clinicaltrials.gov/ct2/show/NCT03794076
Mar 8th, 2022 - Schizophrenia (SZ) extracts a heavy personal and public health cost, primarily because there is no effective treatment. Though many drugs are currently available, the majority provide only partial relief for psychotic phenomena and none guarantee ...
News 44 results
https://www.onclive.com/view/avapritinib-approved-in-europe-for-advanced-systemic-mastocytosis
Mar 25th, 2022 - The European Commission has expanded the current indication for avapritinib (Ayvakyt) to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast ...
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types
Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....
https://www.onclive.com/view/eu-panel-recommends-avapritinib-for-advanced-systemic-mastocytosis
Jan 31st, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended to expand the current indication for avapritinib (Ayvakyt) to include use as a single agent in the treatment of adult patients with aggressive sy...
https://www.medscape.com/viewarticle/962196
Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...
https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment
Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...